Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine

AbbottAbbott has been named to Hispanic Business magazine's list of the nation's best companies for Hispanics. Abbott was recognized as one of the magazine's "Diversity Elite 60" companies for its commitment to Hispanic hiring, promotion, marketing, philanthropy and supplier diversity.

"As an innovation-driven company, Abbott relies on the diversity of our people to provide different ideas, perspectives and experience that enable us to translate science into new solutions for patients," said Stephen Fussell, senior vice president, Human Resources, Abbott.

Diversity a Long-Standing Priority for Abbott
Abbott's commitment to diversity starts at the top with the company's Chairman and Chief Executive Officer Miles D. White, who chairs the company's Executive Inclusion Council. The Council oversees the company's diversity and inclusion efforts, monitors the hiring and advancement of women and minorities in management, and supports programs that promote an inclusive work environment for all employees.

Abbott maintains aggressive goals for the recruitment, hiring and retention of women and minorities. Minorities at Abbott make up more than one-quarter (26 percent), and women nearly one-half (47 percent), of Abbott's total U.S. workforce. Abbott has increased the number of minorities in management by 68 percent and the number of women in management by 64 percent over the past five years.

More than 7,700 employees participate in Abbott's employee networks, which play a vital role in building more diverse leadership within Abbott. These include: LA VOICE Network (Hispanic/Latino), Women Leaders in Action, Black Business Network, Asian Cultural Leadership Network, PRIDE Network gay/lesbian) and the Part-Time Network. By focusing on career development, mentoring, informal networking and work-life integration, Abbott's active networks offer leadership and expanded advancement opportunities for women and minorities. Each network is sponsored by a member of senior management who helps align the group's objectives with Abbott's business strategy.

Abbott Widely Recognized as a Premier Employer
In addition to being included in Hispanic Business magazine's "Diversity Elite 60," Abbott has been included on DiversityInc magazine's list of the "Top 50 Companies for Diversity" for four years. The company was named one of the "Top 50 Companies for Black MBAs to Work" by Black MBA magazine, and has been recognized for many years by FORTUNE magazine as one of the "Best Companies for Minorities."

Abbott also has been included in Working Mother magazine's "100 Best Companies for Working Mothers" for the past seven years, has been named one of the "50 Best Places to Launch a Career" by BusinessWeek and was included in the 2008 edition of the Princeton Review's Best Entry-Level Jobs. In addition, Abbott has been recognized by Science and The Scientist magazines as a top employer for scientists, and FORTUNE has named Abbott as one of "America's Most Admired Companies" every year since the list's inception in 1983.

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...